US 11542312
IL-2 superagonists in combination with anti-PD-1 antibodies
granted A61KA61K2039/505A61K2039/5256
Quick answer
US patent 11542312 (IL-2 superagonists in combination with anti-PD-1 antibodies) held by Medicenna Therapeutics Inc. expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Medicenna Therapeutics Inc.
- Grant date
- Tue Jan 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 15
- CPC classes
- A61K, A61K2039/505, A61K2039/5256, A61K2039/55533, A61K35/76